Authors’ Reply to Robert P. Giugliano and Colleagues’ Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”
- 24 February 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 44 (4), 505-506
- https://doi.org/10.1007/s40264-021-01054-2
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”Drug Safety, 2021
- The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and ProarrhythmiaCurrent Heart Failure Reports, 2020
- Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBaseDrug Safety, 2020
- Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from PharmacovigilanceDrug Safety, 2020
- Interstitial Lung Disease as an Adverse Drug Reaction in Japan: Exploration of Regulatory Actions as a Basis for High ReportingDrug Safety, 2020
- ‘Real-world’ observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS)EP Europace, 2019
- Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety ReportsDrug Safety, 2019
- Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systemsNutrition, Metabolism and Cardiovascular Diseases, 2018
- Good Signal Detection Practices: Evidence from IMI PROTECTDrug Safety, 2016
- Drug-induced interstitial lung disease: mechanisms and best diagnostic approachesRespiratory Research, 2012